C
Comera Life Sciences
Enhancing therapeutic protein formulations for better patient experience and extended product lifecycle
About Comera Life Sciences
Comera Life Sciences operates in the life sciences sector, focusing on transforming intravenous (IV) biologics into subcutaneous (SQ) self-administered injections. This innovation aims to provide patients with the freedom to administer their own medication, reducing the need for time-consuming and costly visits to infusion centers. The company serves patients with significant diseases who rely on biologic therapeutics, offering them a more convenient and less painful treatment option. Comera's business model revolves around developing and commercializing these self-injectable biologics, generating revenue through product sales and potential partnerships with pharmaceutical companies. By leveraging their proprietary platform, Comera aims to maximize the therapeutic potential of biologics, ultimately improving patient outcomes and quality of life.
Source: Dealroom company dataAt a glance
- Founded
- 2014
- Headquarters
- Woburn, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
KBI Biopharma
Phoenix Venture Partners- MCMBL Venture Capital
Series B and later1 investor entered at this stage
OTR Acquisition Corp
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Comera Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Comera Life Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.